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and the IberoAmerican Cryptococcal Study Group1
A network was established to acquire basic knowledge of
Cryptococcus neoformans in IberoAmerican countries. To this
effect, 340 clinical, veterinary, and environmental isolates from
Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela,
Guatemala, and Spain were typed by using M13 polymerase
chain reaction-fingerprinting and orotidine monophosphate pyro-
phosphorylase (URA5) gene restriction fragment length polymor-
phsm analysis with HhaI and Sau96I in a double digest. Both
techniques grouped all isolates into eight previously established
molecular types. The majority of the isolates, 68.2% (n=232),
were VNI (var. grubii, serotype A), which accords with the fact
that this variety causes most human cryptococcal infections
worldwide. A smaller proportion, 5.6% (n=19), were VNII (var.
grubii, serotype A); 4.1% (n=14), VNIII (AD hybrid), with 9 iso-
lates having a polymorphism in the URA5 gene; 1.8% (n=6),
VNIV (var. neoformans, serotype D); 3.5% (n=12), VGI; 6.2%
(n=21), VGII; 9.1% (n=31), VGIII, and 1.5% (n=5) VGIV, with all
four VG types containing var. gattii serotypes B and C isolates.
ryptococcosis is among the most prevalent life-threaten-
ing mycoses and has a worldwide distribution. The etio-
logic agent is the basidiomycetous yeast Cryptococcus
neoformans (1,2); three varieties are recognized: C. neofor-
mans var. grubii, serotype A (3), C. neoformans var. neofor-
mans, serotype D, C. neoformans var. gattii, serotypes B and
C, and the hybrid serotype AD (4).
Humans are infected by inhaling infectious propagules
from the environment, which primarily colonize the lung and
subsequently invade the central nervous system (4). C. neofor-
mans var. grubii/neoformans has been isolated worldwide
from soil enriched with avian excreta (4,5). More recently,
decaying wood from certain species of trees has been proposed
as environmental habitat for this variety (6). In contrast, the
distribution in nature for C. neoformans var. gattii is geograph-
ically restricted to mainly tropical and subtropical regions
(7,8). To date, specific host trees are represented by Eucalyp-
tus species, Moquilea tomentosa, Cassia grandis, Ficus micro-
capra, and Terminalia catappa (7–11). 
Worldwide, in immunocompromised hosts, most infec-
tions are caused by C. neoformans var. grubii (4,5). In con-
trast,  C. neoformans var.  gattii virtually always affects
immunocompetent hosts (8).
In the last decade, a number of DNA typing techniques
have been used to study the epidemiology of C. neoformans.
These techniques include karyotyping, random amplification
of polymorphic DNA, restriction fragment length polymor-
phism (RFLP), DNA hybridization studies, amplified frag-
ment length polymorphism (AFLP), and polymerase chain
reaction (PCR) fingerprinting (12–17). 
PCR fingerprinting has been used as the major typing tech-
nique in the ongoing global molecular epidemiologic survey of
C. neoformans (14,18), dividing >400 clinical and environ-
mental isolates into eight major molecular types: VNI (var.
grubii, serotype A), VNII (var. grubii, serotype A), VNIII
(serotype AD), VNIV (var. neoformans, serotype D), VGI,
VGII, VGIII, and VGIV (var. gattii, serotypes B and C). No
correlation between serotype and molecular type has been
found for C. neoformans var. gattii. The molecular types were
recently confirmed by RFLP analysis of the orotidine mono-
phosphate pyrophosphorylase (URA5) gene and the phospholi-
pase (PLB1) gene (19). 
Globally, most of the isolates recovered from AIDS
patients belong to the genotypes VNI and VNIV, whereas the
genotypes VNI and VGI are predominant throughout the
world for C. neoformans var. grubii and C. neoformans var.
gattii, respectively. The larger number of genotype VNI iso-
lates agrees with the fact that C. neoformans var. grubii causes
most human cryptococcal infections worldwide (18,19). 
The aims of this study were the following: 1) to extend the
molecular epidemiologic survey to other parts of the world, 2)
to establish a regional network of participating reference labo-
ratories, and 3) to apply PCR fingerprinting and URA5 RFLP
typing to investigate the genetic structure and possible epide-
miologic relationships between clinical and environmental iso-
lates obtained in Latin America and Spain. The results of this
study permitted us to determine the major molecular types and
their distribution within each participating country.
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Materials and Methods
Study Design
During the 12th International Society for Human and Ani-
mal Mycoses meeting in Buenos Aires, Argentina, in March
2000, it was decided to establish an IberoAmerican Cryptococ-
cal Study Group under the coordination of E. Castañeda and
W. Meyer. Each of the participating laboratories was asked to
submit 10–30 isolates. For the clinical isolates, the following
data were requested: isolation date, demographic data (age and
gender of patient), collection location, risk factors, source and
variety, and serotype. For the environmental and veterinary
isolates, the data collected included isolation date, source, col-
lection location, variety, and serotype.
Fungal Isolates
An online appendix of cryptococcal isolates studied in this
study is available at: URL: http://www.cdc.gov/ncidod/EID/
vol9no2/02-0246_app.htm. The isolates were obtained by the
participating laboratories of the IberoAmerican Cryptococcal
Study Group and maintained on Sabouraud dextrose agar
slants at 4°C and as water cultures at room temperature. Iso-
lates were identified as C. neoformans by using standard meth-
ods (20). The variety was determined by the color reaction test
on L-canavanine-glycine-bromothymol blue medium (21), and
the serotype was determined, in selected isolates, by the use of
the Crypto Check Kit (Iatron Laboratories Inc., Tokyo, Japan).
The isolates were sent for molecular typing to the Molecu-
lar Mycology Laboratory at the University of Sydney at West-
mead Hospital, Sydney, Australia, either as water cultures or
on Sabouraud dextrose agar slants. For long-term storage, the
isolates were maintained as glycerol stocks at –70°C.
Reference Strains
A set of laboratory standard C. neoformans reference
strains representing each molecular type were used in PCR fin-
gerprinting and URA5 RFLP as follows: WM 148 (serotype A,
VNI), WM 626 (serotype A, VNII), WM 628 (serotype AD,
VNIII), WM 629 (serotype D, VNIV), WM 179 (serotype B,
VGI), WM 178 (serotype B, VGII), WM 161 (serotype B,
VGIII), and WM 779 (serotype C, VGIV) (14).
DNA Extraction
High-molecular-weight DNA was isolated as described
previously (14). Briefly, C. neoformans isolates were grown
on Sabouraud’s dextrose agar at 37°C for 48 h, a loopful of
cells from the culture was mixed with sterile deionized water
and centrifuged. The supernatant was discarded, and the tube
containing the yeast cell pellet was frozen in liquid nitrogen.
The pellet was ground with a miniature pestle. The cell lysis
solution (100 mg triisopropylnapthalene sulfonic acid, 600 mg
para-aminosalicylic acid, 10 mL sterile deionized water, 2.5
mL extraction buffer (1 M Tris-HCl, 1.25 M NaCl, 0.25 M
EDTA, pH 8.0) and 7.5 mL phenol saturated with Tris-EDTA
was preheated to 55°C, and 700 µL of this mixture was added
to the frozen, ground cells. The tubes were incubated for 2 min
at 55°C, shaken occasionally, and then 500 µL chloroform was
added, and the mixture was incubated for a 2 min at 55°C and
shaken occasionally. The tubes were centrifuged for 10 min at
14,000 rpm, and the aqueous phase was transferred to a new
tube. Then, 500 µL of phenol-chloroform-isoamyl alcohol
(25:24:1) was added, shaken for 2 min at room temperature,
and centrifuged as above. The aqueous phase was transferred
to a new tube, 500 µL of chloroform was added, shaken, and
centrifuged as above. To precipitate the genomic DNA, the
aqueous phase was again transferred to a new tube, and 0.03
volumes 3.0 M sodium acetate (pH 5.2) and 2.5 volumes cold
96% ethanol were added, and the mixture was gently shaken
and incubated at –20°C for at least 1 h or overnight. The solu-
tion was centrifuged for 30 min at 14,000 rpm to pellet the
DNA. The DNA pellet was washed with 70% ethanol and cen-
trifuged for 10 min at 14,000 rpm and air-dried. The DNA was
resuspended in 200 µL sterile deionized water at 4°C over-
night and stored at –20°C.
PCR Fingerprinting
The minisatellite-specific core sequence of the wild-type
phage M13 (5′  GAGGGTGGCGGTTCT 3′ ) (22) was used as
single primer in the PCR. The amplification reactions were
performed in a volume of 50 µL containing 25 ng high-molec-
ular-weight genomic DNA, 10 mM Tris-HCl, pH 8.3, 50 mM
KCl, 1.5 mM MgCl, 0.2 mM  each of the dATP, dCTP, dGTP
and dTTP (Roche Diagnostics GmbH, Mannheim, Mannheim,
Germany), 3 mM magnesium acetate, 30 ng primer, and 2.5 U
Amplitaq DNA polymerase (Applied Biosystems, Foster City,
CA). PCR was performed for 35 cycles in a Perkin-Elmer ther-
mal cycler (model 480) with 20 s of denaturation at 94°C, 1
min annealing at 50°C, and 20 s extension at 72°C, followed
by a final extension cycle for 6 min at 72°C. Amplification
products were removed, concentrated to approximately 20 µL
and separated by electrophoresis on 1.4% agarose gels (stained
with ethidium bromide, 10 mg/mL stock) in 1X Tris-borate-
EDTA (TBE) buffer at 60 V for 14 cm, and visualized under
UV light (14). Molecular types (VNI–VNIV and VGI–VGIV)
were assigned, according to the major bands in the patterns.
All visible bands were included in the analysis, independent of
their intensity (14,18).
URA5 Gene RFLP
PCR of the URA5 gene was conducted in a final volume of
50 µL. Each reaction contained 50 ng of DNA, 1X PCR buffer
(10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2;
Applied Biosystems, Foster City, CA), 0.2 mM each of dATP,
dCTP, dGTP, and dTTP (Roche Diagnostics GmbH), 3 mM
magnesium acetate, 1.5 U AmpliTaq DNA polymerase (Applied
Biosystems), and 50 ng of each primer URA5 (5′ ATGTCCTC-
CCAAGCCCTCGACTCCG 3′ ) and SJ01 (5′  TTAAGAC-
CTCTGAACACCGTACTC 3′ ). PCR was performed for 35
cycles in a Perkin-Elmer thermal cycler (model 480) at 94°C for
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annealing at 61°C, and 2-min extension at 72°C, followed by a
final extension cycle for 10 min at 72°C. Amplification products
were mixed with one fifth volume of loading buffer (15% Ficoll
400, 0.25% orange G, MilliQ water), 15 µL of PCR products
were double digested with Sau96I (10 U/µL) and HhaI (20 U/
µl) for 3 h or overnight and separated by 3% agarose gel electro-
phoresis at 100 V for 5 h. RFLP patterns were assigned visually
by comparing them with the patterns obtained from the standard
strains (VNI-VNIV and VGI-VGIV) (Jackson et al. unpub.
data).
Statistical Analysis
Initially, individual PCR fingerprints were visually com-
pared to those of the standard strains, amplified in parallel, to
determine the major molecular type for each isolate. The com-
puter program GelComparII, version 1.01 (Applied Maths,
Kortrijk, Belgium) was used to determine the genetic relation-
ship of the strains. DNA bands of each fingerprint pattern were
defined manually with a band-position tolerance of 0.9%,
being the optimal settings needed to define the molecular size
marker bands as 100% identical. Similarity coefficients were
calculated by using the Dice algorithm, and cluster analyses
were performed by the neighbor-joining algorithms by using
the “Fuzzy Logic” and “Area Sensitive” option of the Gelcom-
parII program.
Results
During the course of this investigation, a network was estab-
lished with 15 laboratories from nine countries participating in this
study. The participant countries were: Argentina, Brazil, Chile,
Colombia, Guatemala, Mexico, Peru, Spain, and Venezuela.
A total of 340 C. neoformans isolates, comprising 266
clinical, 7 veterinary, and 67 environmental isolates were sub-
mitted for molecular typing. Of these, 57 were from Argentina
(53 clinical and 4 environmental), 66 from Brazil (56 clinical,
9 environmental, and 1 veterinary), 19 from Chile (15 clinical
and 4 environmental), 62 from Colombia (39 clinical and 23
environmental), 15 from Guatemala (all clinical), 69 from
Mexico (46 clinical and 23 environmental), 13 from Peru (all
clinical), 19 from Spain (9 clinical, 6 veterinary, and 4 envi-
ronmental), and 20 from Venezuela (all clinical). From the
total isolates investigated, 271 (79.6%) were C. neoformans
var. grubii/neoformans; 251 (92.6%) of them were C. neofor-
mans var. grubii, 6 (1.8%) were C. neoformans var. neofor-
mans, and 13 (4.8%) were AD hybrid isolates. The remaining
69 (20.4%) isolates were C. neoformans var. gattii.
All 340 isolates were typed by PCR fingerprinting by using
the minisatellite-specific oligonucleotide M13 as a single
primer and RFLP analysis of the URA5 gene with the restric-
tion enzymes Sau96I and HhaI in a double digest. The molecu-
lar types were determined for each isolate by comparing the
obtained PCR fingerprint profiles and URA5 RFLP patterns
with the respective standard patterns for each molecular type. 
The serotyping results (Iatron) correlated with the molecu-
lar subtyping results in all serotype B (n=31) and C (n=13) iso-
lates. Regarding serotype A, 99 from a total of 102 (97%)
isolates correlated; the remaining 3 were serotype A by the
Iatron and serotype AD by the molecular typing method.
Regarding serotype D, one of four reported was confirmed by
molecular typing; the other three were serotype AD. For sero-
type AD, two isolates were found when typed with the Iatron
kit and eight when typed with molecular typing techniques.
All the changes were found in the isolates from Spain. This
finding is not surprising, taking into account that problems
with the serotyping concerning potential serotype AD hybrids
are known (4). A list of  the characteristics of the studied iso-
lates by participating country, laboratory, laboratory code,
clinical, veterinary or environmental origin, isolate character-
istics (isolation year, isolation location, source, gender, age
and risk factor), variety, serotype and the molecular type iden-
tified during this study is available in an online appendix
(http://www.cdc.gov/ncidod/EID/vol9no2/02-0246_app.htm). 
Both molecular typing techniques grouped the isolates in
the eight previously established major genotypes (Figures 1 and
2). From the isolates investigated, 232 (68.2%) were molecular
type VNI (serotype A, var. grubii), 19 (5.6%) were molecular
type VNII (serotype A, var. grubii), 14 (4.1%) were molecular
type VNIII (serotype A/D, hybrid between the serotypes A and
D), with 5 having a RFLP pattern of the URA5 gene with seven
bands, indicated by VNIII in the online Appendix and Figure
3B and 4B, corresponding to a hybrid between VNI, VNII, and
VNIV and 9 isolates having an RFLP pattern of the URA5 gene
with six bands, indicated by VNIII* in the online Appendix and
Figure 4B and 5B, corresponding to a hybrid between VNII and
VNIV, 6 (1.8%) were molecular type VNIV (serotype D, var.
neoformans), 12 (3.5%) were molecular type VGI (serotypes B
and C, var. gattii), 21 (6.2%) were molecular type VGII (sero-
types B and C, var. gattii), 31 (9.1%) were molecular type
VGIII (serotypes B and C, var. gattii), and 5 (1.5%) were
molecular type VGIV (serotypes B and C, var. gattii). 
Figures 3A and 4A show examples of PCR fingerprints
obtained from Mexican and Spanish isolates; Figures 3B and
4B show the corresponding URA5 RFLP patterns for the same
isolates. The Mexican isolates were selected because they
were representative of the patterns observed from all the iso-
lates submitted by the Latin American participating laborato-
ries. The Spanish isolates were selected because they
represented a distribution of molecular types corresponding to
those observed in previous studies on European isolates (14). 
From the 340 isolates studied 277, marked with “#” in the
online Appendix, have been included in the GelComparII anal-
ysis. Sixty-three isolates were excluded from the analysis
since their PCR fingerprinting patterns were not sharp or had
been run under slightly different electrophoresis conditions,
making the band positions impossible to compare. Cluster
analysis of the PCR-fingerprinting profiles by using the
GelComparII program grouped all isolates into three major
clusters according to variety and into eight major groups
according to the molecular type. The overall homology
observed was 50.4% among isolates of C. neoformans var.RESEARCH
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grubii, 50.9% for C. neoformans var. neoformans, and 51.2%
for C. neoformans var. gattii (Figure 2). The homology within
a given molecular type was as follows: 54.8% VNI, 57.3%
VNII, 51.9% VNIII, 50.9% VNIV, 56.4% VGI, 56.4% VGII,
54.4% VGIII, and 68.3% VGIV. 
Besides grouping all isolates into the eight major molecu-
lar patterns, the molecular type VNI could be subdivided into
eight main subclusters, with most of these subclusters’ group-
ing isolates obtained from specific countries. The similarity
between isolates obtained from any individual country varied
from 65% to 82%. Most of the main subclusters within molec-
ular type VNI also contained isolates from different countries,
indicating gene flow and strain dispersal between South Amer-
ican countries, Spain, or both. However, all isolates could be
separated by their unique PCR-fingerprinting pattern, with the
highest homology being 84% between two unrelated environ-
mental isolates from Mexico City (LA 22, budgerigar [para-
keet] droppings, and LA 25, pigeon droppings). 
Of the 266 clinical isolates, 177 (66.5%) were obtained
from HIV-positive patients, with 139 (78.5%) being VNI, 14
(7.9%) VNII, 13 (7.4%) VNIII, 6 (3.4%) VNIV, 3 (1.7%) VGII,
and 2 (1.1%) VGIII. Most (86.4%) isolates from HIV-positive
patients belonged to the molecular types VNI and VNII, repre-
senting serotype A, C. neoformans var. grubii. Of these, 266
clinical isolates, 51 (19.2%) were recovered from patients with
no reported risk factors. From those, 23 (45.1%) were var. gru-
bii with the molecular type VNI (n=21) or VNII (n=2), and 28
(54.9%) were var. gattii with the molecular types VGI (n=3),
VGII (n=10), VGIII (n=14), and VGIV (n=1). For 26 of the
clinical isolates, no data concerning risk factors were available.
Six veterinary isolates were molecular type VGI, and one was
VGII. Most of the environmental isolates belonged to C. neo-
formans var. grubii with 73.1% being VNI (n=49) and 1.5%
VNIII (n=1) AD hybrids. The remaining 17 (25.3%) isolates
were C. neoformans var. gattii with the molecular type VGI
(n=1), VGII (n=3), VGIII (n=12), and VGIV (n=1).
Cryptococcal isolates included in the IberoAmerican study
were more frequently obtained from men than from women.
The male-to-female ratio was 2l1 to 41, i.e., cryptococcosis
was 5.1 times more common in men than in women. In the
HIV-positive population alone, the incidence of cryptococco-
sis was 5.5 times more frequent in men than in women, based
on the data obtained from the isolates investigated in this
study. The age of the patients with clinically manifested cryp-
tococcosis ranged from 4 to 73; 175 (65.9%) were between 21
and 40 years old.
The clinical isolates submitted to this study were collected
over a period of 41 years, 1961–2001; most (92.5%) of the iso-
lates were collected in the mid-1990s. The veterinary isolates
were recovered from goats in Spain in 1995 and from a parrot
in Brazil in 2000. The environmental isolates submitted were
collected over a period of 7 years, 1993–2000.
Discussion
This retrospective study of cryptococcosis in IberoAmer-
ica was set up in an effort to establish a network of medical
Figure 1.  Geographic distribution of the molecular types obtained from
IberoAmerican  Cryptococcus neoformans isolates by polymerase chain
reaction fingerprinting and URA5 gene restriction fragment length polymor-
phis analysis (total numbers studied per country given in parentheses).
Figure 2. Dendrogram of the polymerase chain reaction-fingerprinting
patterns obtained with the primer M13 from a selection of the
IberoAmerican isolates studied. All the isolates fall into eight major
molecular types, which fall into three major groups corresponding to
Cryptococcus neoformans var. grubii, serotype A, with two molecular
types VNI and VNII; C. neoformans var. neoformans, serotype D, with
the molecular type VNIV; and C. neoformans var. gattii serotypes B and
C, with the molecular types VGI, VGII, VGIII and VGIV. In addition to
the three major clusters we can see the intermediate molecular type
VNIII, representing the AD hybrids.Emerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 193
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mycology laboratories to study the distribution of cryptococcal
isolates, including the varieties and molecular types within the
participating countries. The network was aimed at generating
PCR-fingerprint and URA5 RFLP patterns under standardized
conditions in the Molecular Mycology Laboratory of the Uni-
versity of Sydney at Westmead Hospital, for a subset of clini-
cal and environmental C. neoformans isolates from each
participating country. These reference profiles are now avail-
able to each participating laboratory so they can set up the
molecular typing techniques in their own laboratories, and to
serve as internal controls in future extended studies of crypto-
coccal isolates in each country. 
The data were obtained from a random selection of crypto-
coccal isolates from each participating country and laboratory,
which do not necessarily reflect the true situation in
IberoAmerica. Nonetheless, the data offer a general overview
of molecular types and variety distribution of C. neoformans
in IberoAmerica. For the first time, two different molecular
typing techniques, PCR-fingerprinting with the minisatellite
specific primer M13 and URA5 gene RFLP analysis, were
applied simultaneously to the same set of cryptococcal iso-
lates, demonstrating identical groupings to the eight major
molecular types previously described (14,18).
Previous pilot studies that used PCR-fingerprinting at the
University of Sydney at Westmead Hospital distributed more
than 400 clinical and environmental isolates obtained from
Argentina, Australia, Belgium, Brazil, Germany, Italy, New
Zealand, Papua New Guinea, South Africa, Thailand, Uganda,
and the United States in eight major molecular types, VNI and
VNII (serotype A), VNIII (serotype AD), VNIV (serotype D),
VGI, VGII, VGIII and VGIV (serotypes B and C) (14,18). At
the time of this original work, the molecular types VNI and
VGI were found to be the most common genotypes world-
wide. The present study, which includes more isolates from
Latin America, showed the same results as regards variety
grubii, with VNI being the predominant molecular type,
accounting for 68.2% of all isolates. However, the situation
changed drastically for variety gattii; as in this study, the pre-
dominant molecular type was VGIII, accounting for 9.1% of
all isolates, in contrast to previous studies which showed that
the molecular type VGIII was geographically restricted to
India and the United States (18,19). In the present study, VGIII
was also found in Argentina, Colombia, Guatemala, Mexico
Figure 3. Polymerase chain reaction (PCR) fingerprints generated with
the primer M13 (3A), and URA5 gene restriction fragment length poly-
morphism (RFLP) profiles identified by double digest of the gene with
Sau96I and HhaI (3B) obtained from a selection of Mexican Cryptococ-
cus neoformans isolates, given as a representative example for the
patterns obtained from clinical and environmental isolates from Latin
America. Standard patterns obtained from the reference strains of the
major molecular types by PCR-fingerprinting patterns with the micro-
satellite specific primer M13 as a single primer in the PCR (right-hand
side of 3A)  and  URA5 gene  RFLP profiles generated after double
digest with Sau96I and HhaI (right-hand side of 3B) (VNIII correspond
to the seven-band URA5 RFLP pattern and VNIII* correspond to the
six-band URA5 RFLP pattern).
Figure 4.  Polymerase chain reaction fingerprints generated with the
primer M13 (4A) and URA5 gene restriction fragment length polymor-
phism (RFLP) profiles identified via double digest of the gene with
Sau96I and HhaI (4B) obtained from the Spanish clinical, veterinary,
and environmental Cryptococcus neoformans isolates (VNIII corre-
spond to the seven-band URA5 RFLP pattern and VNIII* correspond to
the six-band URA5 RFLP pattern). 100bp MassRuler used as molecu-
lar marker in 4B.RESEARCH
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and Venezuela, suggesting that it is not as limited as previ-
ously suggested. The same was true for the molecular type
VGIV, previously assigned only to India and South Africa
(18,19); its presence in Colombia and Mexico, although in
very low numbers, indicates a wider geographic distribution.
In general, the most common variety was C. neoformans
var. grubii, 73.8% (n=251), followed by variety gattii, 20.3%
(n=69). Much less common were the AD hybrids, 4.1% (n=14)
and variety neoformans, 1.8% (n=6), which reflects the global
distribution previously established (14,18,23).
The overall grouping of the isolates into eight major
molecular types by PCR-fingerprinting with the minisatellite
specific primer M13, obtained in this study and the previous
pilot study by Meyer et al. 1999 (14) and Ellis et al. 2000 (18),
agrees with the findings by Boekhout et al. 2001 (23) and by
Cogliati et al. in 2000 (24). Boekhout et al. (23) used AFLP
analysis to study 206 global isolates of C. neoformans, and
grouped them into six major AFLP groups, whereas Cogliati et
al.  (24), using a slightly modified PCR-fingerprinting tech-
nique with the microsatellite specific primer (GACA)4,
grouped Italian isolates of C. neoformans var. grubii and var.
neoformans into four major molecular types. Comparable
molecular/genotypes, which where identified in the four cited
independent studies, are VNI = AFLP1 = Cogliati VN6 (sero-
type A, var. grubii); VNII = AFLP1A (serotype A, var. grubii);
VNIII = AFLP3 = Cogliati VN3 and VN4 (serotype AD,
hybrid between var. grubii and var. neoformans); VNIV =
AFLP2 = Cogliati VN1 (serotype D, var. neoformans); VGI =
AFLP4, VGII = AFLP6, VGIII = AFLP5 and VGIV (all corre-
sponding to serotypes B and C, var. gattii) (14,18,23,24).
The overall results show some clonality between isolates
obtained from a certain country or even between different
countries, suggesting partial clonal spread of the pathogenic
yeast within South America. However, the approximately
50%, overall similarity between C. grubii isolates, with the
highest being 82%, suggests that these South American iso-
lates are more varied than those obtained in a previous study
by Franzot et al. (25), in which they examined a limited num-
ber of isolates from Brazil by using less discriminatory molec-
ular techniques (CNRE-1 RFLP analysis and URA5
sequencing). In Franzot’s study, the highest similarity was
>94% between the Brazilian isolates, suggesting a higher
clonality than observed in the isolates obtained from New
York City studied in the same paper (25).
Interestingly, Chile and Spain share similar molecular
types. Both countries have a large number of molecular type
VNIII isolates (AD hybrids), 15.8% and 42.1%, respectively,
although VNIV serotype D isolates were present only in Chile
(26.3%). These groups are usually common in a number of
European countries, such as France and Italy (26–28). How-
ever, only these two countries show two different URA5 RFLP
patterns, one consisting of seven bands, indicating a hybrid
between VNI, VNII, and VNIV, and a second new hybrid
URA5 RFLP pattern, consisting of six bands, indicating a
hybrid between VNII and VNIV. As a result of the IberoAmeri-
can study, these hybrid patterns had recently been reported as
part of Jackson’s honor’s thesis work (Jackson and Meyer
unpub. data, 2000). The seven-band URA5 RFLP pattern was
exclusively found in Spain (n=3) and Chile (n=2). These strains
seem to be triploid, and cloning with subsequent sequencing of
the PCR product showed that they contain three different cop-
ies of the URA5 gene. The six-band URA5 RFLP pattern found
in Spain (n=5) and Chile (n=1), was also found in Mexico
(n=1) and Argentina (n=2), possibly due to the presence of the
molecular types VNII and VNIV in these countries (14). These
hybrid isolates are diploid at the URA5 locus and contain two
different copies of the gene (Jackson and Meyer, unpub. data). 
Further studies are needed to investigate the special rela-
tionship between isolates obtained from these two countries.
The similarity in the molecular types obtained from Spanish
and Chilean isolates provides further evidence, that the crypto-
coccal strains present today in South America could be intro-
duced during the European colonization. This idea had been
suggested by Franzot et al. (25) when investigating isolates
obtained from Brazil. The authors argue that the pigeon
(Columba livia), thought to provide a major reservoir of C.
neoformans in pigeon excreta, is believed to have originated in
southern Europe and northern Africa and has been dispersed
worldwide by human travel (29).
Most of the cryptococcal isolates in this study were recov-
ered from patients whose main risk factor was HIV infection.
Overwhelming numbers of these isolates corresponded to the
molecular type VNI, in accordance with previous findings,
showing that isolates of this molecular type are the major
source of infection in HIV-positive patients worldwide
(18,19). This finding highlights the fact that most human cryp-
tococcal infections are caused by C. neoformans var. grubii,
serotype A (4,5). A distinct picture emerged in the group of
isolates obtained from patients with no known risk factors, as
most were C. neoformans var. gattii isolates (n=28), with the
molecular types VGI (n=3), VGII (n=10), VGIII (n=14), and
VGIV (n=1), compared to 23 isolates belonging to the overall
most common molecular type, VNI (41.2%) of C. neoformans
var. grubii. This finding supports the conclusion that variety
gattii primarily infects immunocompetent patients as Chen et
al.  had  found when investigating Australian isolates (30).
These authors have proposed that aboriginal people living in
rural areas of Australia’s Northern Territory have a higher risk
of cryptococcosis because they live in close proximity to the
potential natural host of C. neoformans var. gattii, the eucalyp-
tus trees (30).
Despite the fact that isolates included in this study consti-
tuted a random sampling, the results show again that HIV
infection is the most important risk factor for cryptococcosis
(31). This conclusion is supported by the number of isolates
recovered from HIV-positive patients (n=177), the age distri-
bution, which peaks between 20 and 40 years of age, and the
date of isolation with a peak corresponding to the 1990s. 
Overall, the network of mycology laboratories established
in IberoAmerica provided, for the first time, a baseline knowl-Emerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 195
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edge of C. neoformans variety and molecular type distribution
in the participating countries, placing the IberoAmerican iso-
lates in the global picture of cryptococcosis. 
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